Rosalind Advisors Inc. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Rosalind Advisors Inc. lifted its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 41.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,062,500 shares of the company’s stock after buying an additional 312,500 shares during the period. Trevi Therapeutics makes up approximately 2.2% of Rosalind Advisors Inc.’s portfolio, making the stock its 17th biggest holding. Rosalind Advisors Inc.’s holdings in Trevi Therapeutics were worth $4,378,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. GSA Capital Partners LLP bought a new stake in Trevi Therapeutics during the third quarter worth $409,000. Geode Capital Management LLC increased its position in shares of Trevi Therapeutics by 10.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after purchasing an additional 117,418 shares during the last quarter. Fred Alger Management LLC bought a new stake in shares of Trevi Therapeutics during the 3rd quarter worth $256,000. JPMorgan Chase & Co. boosted its holdings in shares of Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after buying an additional 69,167 shares during the last quarter. Finally, Barclays PLC grew its position in Trevi Therapeutics by 180.8% during the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after buying an additional 61,317 shares during the period. 95.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on TRVI shares. Needham & Company LLC lowered their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. HC Wainwright reissued a “buy” rating and set a $12.50 price objective on shares of Trevi Therapeutics in a report on Wednesday. D. Boral Capital reissued a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday. Finally, B. Riley reaffirmed a “buy” rating and set a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $17.56.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $6.47 on Friday. Trevi Therapeutics, Inc. has a one year low of $2.30 and a one year high of $7.39. The business has a fifty day moving average price of $4.60 and a 200-day moving average price of $3.75. The firm has a market capitalization of $497.32 million, a P/E ratio of -14.70 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. Sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Farrell Simon sold 81,313 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now owns 76,900 shares of the company’s stock, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 24.37% of the stock is owned by company insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.